Artiva Therapeutics shuts down after two deaths in autoimmune cell therapy trial
Two patient deaths in Artiva Therapeutics' autoimmune cell therapy trial have prompted the company to close, dealing a setback to the field of applying cancer cell-therapy strategies to autoimmune disease.
Artiva Therapeutics has announced it is shutting down following two deaths in its clinical trial investigating cell therapy for autoimmune disease. The trial applied approaches derived from cancer cell therapy — specifically natural killer cell-based strategies — to patients with autoimmune conditions, a field that has attracted considerable interest following early successes with CAR-T cell therapy in haematological malignancies.
The deaths represent a significant safety signal for this nascent therapeutic area. Several companies and academic groups have been investigating whether the deep immune resets seen with cell therapy in cancer could be translated to severe autoimmune diseases, with some early trials reporting encouraging remissions. The Artiva setback, reported by Stat News on 27 October 2026, is the latest in a series of safety events in this space — Genetic Current previously reported a patient death in a Bristol Myers Squibb CAR-T autoimmune trial on 24 October 2026.
The events underscore that cell therapies applied outside their original oncology context carry poorly characterised risks, and that the immunological dynamics in autoimmune disease differ substantially from those in haematological cancers. Researchers, oncologists, and genetic counsellors working with patients who have hereditary autoimmune predispositions should note the ongoing safety questions in this area of translational research.
No clinical recommendations can be drawn from this report; it reflects early-phase clinical trial safety data as reported in the public domain.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-27STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down